Pharvaris N.V.

NASDAQ (USD): Pharvaris N.V. (PHVS)

Last Price

20.55

Today's Change

+0.51 (2.54%)

Day's Change

20.01 - 20.55

Trading Volume

14,947

Profile
PHVS

Exchange:  NASDAQ Global Select NASDAQ Global Select

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. Berndt Axel Edvard Modig CPA, M.B.A. Mr. Berndt Axel Edvard Modig CPA, M.B.A.

Full Time Employees:  83 83

IPO Date:  2021-02-05 2021-02-05

CIK:  0001830487 0001830487

ISIN:  NL00150005Y4 NL00150005Y4

CUSIP:  N69605108 N69605108

Beta:  -3.15 -3.15

Last Dividend:  0.00 0.00

Dcf Diff:  9.82 9.82

Dcf:  10.73 10.73

Description

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

Address

J.H. Oortweg 21,
Leiden, 2333 CH, NL

31 71 203 6410

http://pharvaris.com

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment